| Date Checked | 2025-12-21 23:26:06 |
|---|---|
| Graham Number | (PB)nan vs (PE)0.00 |
| Over / Under Value Percentage | 0.00% vs 0.00% |
| Dividend Yield | 0.00% |
| Dividend Date | None |
| Symbol | SRNE |
| AssetType | Common Stock |
| Name | Sorrento Therape |
| Description | Sorrento Therapeutics, Inc., a commercial and clinical-stage biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. The company is headquartered in San Diego, California. |
| CIK | 850261 |
| Exchange | NASDAQ |
| Currency | USD |
| Country | USA |
| Sector | TRADE & SERVICES |
| Industry | SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH |
| Address | 4955 DIRECTORS PLACE, SAN DIEGO, CA, US |
| FiscalYearEnd | December |
| LatestQuarter | 2022-09-30 |
| MarketCapitalization | 525965000 |
| EBITDA | -390896000 |
| PERatio | 0 |
| PEGRatio | -0.07 |
| BookValue | 0.286 |
| DividendPerShare | 0 |
| EPS | -1.527 |
| RevenuePerShareTTM | 0.161 |
| ProfitMargin | 0 |
| OperatingMarginTTM | -6.69 |
| ReturnOnAssetsTTM | -0.369 |
| ReturnOnEquityTTM | -3.789 |
| RevenueTTM | 60321000 |
| GrossProfitTTM | -167049000 |
| DilutedEPSTTM | -1.527 |
| QuarterlyEarningsGrowthYOY | 0 |
| QuarterlyRevenueGrowthYOY | 0.443 |
| AnalystTargetPrice | 7.67 |
| TrailingPE | - |
| ForwardPE | 1.105 |
| PriceToSalesRatioTTM | 8.29 |
| PriceToBookRatio | 4.008 |
| EVToRevenue | 9.6 |
| EVToEBITDA | -1.141 |
| Beta | 1.956 |
| 52WeekHigh | 3.6 |
| 52WeekLow | 0.74 |
| 50DayMovingAverage | 1.093 |
| 200DayMovingAverage | 1.693 |
| SharesOutstanding | 547880000 |
| ExDividendDate | None |
| naga | 0 |
| etoro | 0 |
| dateChecked | 2025-12-21 23:26:06 |
| fresh | 1 |